Control Bionics (ASX: CBL) registers NeuroStrip with US FDA as commercial execution becomes the next test
Read More Pharma Industry News Foresight Diagnostics strikes licensing deal with Roche for PhasED-Seq in non-Hodgkin’s lymphoma Foresight Diagnostics licenses PhasED-Seq to Roche for Non-Hodgkin’s Lymphoma diagnostics, settling litigation and boosting precision oncology prospects. bySoujanya RaviAugust 30, 2025